CTL Medical Corp. recently announced a partnership with G-21 in Italy to market its bone cement, kyphoplasty and vertebroplasty technologies in the United States. The deal represents a new addition to CTL’s existing spine and orthopedics portfolio.
“With the G-21 partnership, CTL Medical continues to fulfill its mission of becoming a fully integrated medical device design, development and manufacturing company serving the practice of spine surgery,” Daniel Chon, CTL’s president and CEO, said in a July 12 news release.
“We intend to begin immediate distribution of the full line of acrylic-based bone cements for widespread procedures necessary for vertebrae consolidation and stabilization,” Chon said.
The distribution deal’s initial implementation includes providing the FDA-approved bone cement and accompanying kit for the broadly adopted procedure of kyphoplasty, which involves the surgical filling of an injured or collapsed vertebra. The procedure is meant to relieve spinal compression pain.
Each of G-21’s cement kits comes in the form of a two-component system – a liquid and powder –mixed in the surgical suite at the time of application. Various mixtures of the cement compounds are flexible in their working time and viscosity in order to meet health providers’ specific needs.
Dallas-based CTL is a 2-year-old medical device design, development and manufacturing company.
[Want to stay more on top of MDO content? Subscribe to our weekly e-newsletter.]
